# Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology

> **NCT01626547** · — · COMPLETED · sponsor: **Hospira, now a wholly owned subsidiary of Pfizer** · enrollment: 291 (actual)

## Conditions studied

- Chemotherapy-induced Symptomatic Anaemia
- Solid Tumours
- Malignant Lymphomas
- Multiple Myeloma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01626547
- **Lead sponsor:** Hospira, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-12
- **Final completion:** 2013-07
- **Target enrollment:** 291 (ACTUAL)
- **Last updated:** 2017-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01626547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01626547, "Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01626547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*